<DOC>
	<DOC>NCT02601703</DOC>
	<brief_summary>This is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Tacrolimus Ointment, 0.1% (Glenmark Pharmaceuticals, Ltd) to the Marketed Product ProtopicÂ® (tacrolimus) ointment, 0.1% (Astellas Pharma US, Inc.) in the Treatment of Moderate to Severe Atopic Dermatitis (AD).</brief_summary>
	<brief_title>To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Key 1. Nonimmunocompromised male or nonpregnant, nonlactating female, 18 years of age or older with a clinical diagnosis of moderate to severe AD. 2. Have confirmed diagnosis of atopic dermatitis for at least 3 months using the diagnostic features as described by Hanifin and Rajka 3. Have an IGA score of 3 (moderate) or 4 (severe). 4. Have an affected Body Surface Area (BSA) of at least 20% at baseline. 5. Treated with a bland emollient for at least 7 days. Key 1. Active cutaneous bacterial or viral infection in any treatment area at baseline. 2. Sunburn, extensive scarring, or pigmented lesion(s) in any treatment area at baseline. 3. History of confounding skin conditions, e.g., psoriasis, rosacea, erythroderma, or ichthyosis. 4. History or presence of Netherton's Syndrome, immunological deficiencies or diseases, HIV, diabetes, malignancy, serious active or recurrent infection, clinically significant severe renal insufficiency or severe hepatic disorders. 5. Known allergy or hypersensitivity to tacrolimus or any other component of the Study products.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>